4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Burden of Disease in Myasthenia Gravis (Mya-BoD)

Burden of Disease in Myasthenia Gravis (Mya-BoD)

Study Description
Brief Summary:
Questionnaire-based survey addressed to german patients with the chronic autoimmune muscle disease called myasthenia gravis regarding quality of life, socioeconomic impact, social support, course of disease, complications of therapy and psychological comorbidities.

Condition or disease
Myasthenia Gravis

Detailed Description:

Background:

Myasthenia gravis is a rare, chronic, antibody-mediated autoimmune disease that results in muscular weakness. The patients suffer from symptoms such as visual disturbances (especially double vision), weakness in the arms and legs, chewing and swallowing disorders and respiratory disorders, as well as crisis-related worsening of ventilation. This is often accompanied by pronounced fatigue (physical) and mental fatigue (depression).

Despite drug therapies that are on one hand symptomatic improving muscle strength, and on the other hand modulating the immune system, as well as specific procedures and drugs used in crises (plasmapheresis, immunoglobins) or refractory patients, patients are often severely limited, affecting everyday activities of self-care, family, social and professional life, thus affecting the mood and quality of life of patients. There is a lack of data measuring quality of life adequately.

Aim:

The aim of the data collection is to record the quality of life of myasthenia patients. By clinical information on the disease (including symptoms, course and therapy) and recording the social and occupational situation, the data should be contextualized. The following hypotheses are to be confirmed:

Primary hypotheses

  • Myasthenia gravis affects the quality of life of patients comparable to neurological diseases such as multiple sclerosis
  • Patients are limited in their participation in their private and professional life
  • The severity of the disease is associated with the quality of life. Secondary hypotheses
  • Myasthenia is associated with income busses and other economic disadvantages of the night
  • Quality of life in myasthenia patients is related to fatigue and depression
  • Quality of life in myasthenia patients depends on different therapy methods
  • Myasthenia gravis has an impact on family planning and care for children.

Methods:

In cooperation with the German Myasthenia Gravis Society, a questionnaire prepared by the Charité will be sent to its members with a request for completion and an anonymous return. Similar projects have already been implemented in the past (response rate> 30%). About 3,300 patients should be contacted.

The returned questionnaires are then statistically evaluated and presented as part of a publication. For the evaluation of the hypotheses suitable descriptive, univariate analysis methods are used. Furthermore, with sufficient case numbers, multivariate analyzes (e.g., logistic regression) are also planned.

The questionnaire contains general information and questions about:

  • Education and employment
  • Social situation
  • Social Support
  • Economic aspects
  • Symptoms and severity, course, treatment of myasthenia
  • Quality of life
  • Fatigue and depression
Study Design
Layout table for study information
Study Type : Observational
Actual Enrollment : 1680 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Questionnaire Survey on the Systematic Recording and Characterization of Quality of Life Limitations in Myasthenia Gravis
Actual Study Start Date : May 1, 2019
Actual Primary Completion Date : July 31, 2019
Actual Study Completion Date : July 31, 2019
Arms and Interventions
Outcome Measures
Primary Outcome Measures :
  1. Questionnaire for self-completion by patients containing questions about general information, information on myasthenia, information socioeconomic situation [ Time Frame: directly after inclusion in the study ]
  2. Hospital Anxiety and Depression Scale (HADS) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients to determine the levels of anxiety and depression

  3. Mya Quality of Life 15 (Mya QoL15) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients for use as a measure of health outcome

  4. Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF36) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients for patients health

  5. Myasthenia gravis Activities of daily living (MG ADL) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients to determine symptom severity and limitations in activities of daily living


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Myasthenia Gravis being member at the German myasthenia gravis socitey (Deutsche Myasthenie Gesellschaft)
Criteria

Inclusion Criteria:

  • Patients with Myasthenia Gravis
  • Age ≥18 years

Exclusion Criteria:

  • none
Contacts and Locations

Locations
Layout table for location information
Germany
NeuroCure Clinical Research Center (NCRC), Charité University, Berlin
Berlin-Mitte, Germany
Sponsors and Collaborators
Charite University, Berlin, Germany
NeuroCure Clinical Research Center, Charite, Berlin
Investigators
Layout table for investigator information
Principal Investigator: Andreas Meisel, Prof. Dr. med. Charite University, Berlin, Germany
Tracking Information
First Submitted Date June 4, 2019
First Posted Date June 7, 2019
Last Update Posted Date December 9, 2019
Actual Study Start Date May 1, 2019
Actual Primary Completion Date July 31, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 6, 2019)
  • Questionnaire for self-completion by patients containing questions about general information, information on myasthenia, information socioeconomic situation [ Time Frame: directly after inclusion in the study ]
  • Hospital Anxiety and Depression Scale (HADS) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients to determine the levels of anxiety and depression
  • Mya Quality of Life 15 (Mya QoL15) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients for use as a measure of health outcome
  • Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF36) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients for patients health
  • Myasthenia gravis Activities of daily living (MG ADL) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients to determine symptom severity and limitations in activities of daily living
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Burden of Disease in Myasthenia Gravis
Official Title Questionnaire Survey on the Systematic Recording and Characterization of Quality of Life Limitations in Myasthenia Gravis
Brief Summary Questionnaire-based survey addressed to german patients with the chronic autoimmune muscle disease called myasthenia gravis regarding quality of life, socioeconomic impact, social support, course of disease, complications of therapy and psychological comorbidities.
Detailed Description

Background:

Myasthenia gravis is a rare, chronic, antibody-mediated autoimmune disease that results in muscular weakness. The patients suffer from symptoms such as visual disturbances (especially double vision), weakness in the arms and legs, chewing and swallowing disorders and respiratory disorders, as well as crisis-related worsening of ventilation. This is often accompanied by pronounced fatigue (physical) and mental fatigue (depression).

Despite drug therapies that are on one hand symptomatic improving muscle strength, and on the other hand modulating the immune system, as well as specific procedures and drugs used in crises (plasmapheresis, immunoglobins) or refractory patients, patients are often severely limited, affecting everyday activities of self-care, family, social and professional life, thus affecting the mood and quality of life of patients. There is a lack of data measuring quality of life adequately.

Aim:

The aim of the data collection is to record the quality of life of myasthenia patients. By clinical information on the disease (including symptoms, course and therapy) and recording the social and occupational situation, the data should be contextualized. The following hypotheses are to be confirmed:

Primary hypotheses

  • Myasthenia gravis affects the quality of life of patients comparable to neurological diseases such as multiple sclerosis
  • Patients are limited in their participation in their private and professional life
  • The severity of the disease is associated with the quality of life. Secondary hypotheses
  • Myasthenia is associated with income busses and other economic disadvantages of the night
  • Quality of life in myasthenia patients is related to fatigue and depression
  • Quality of life in myasthenia patients depends on different therapy methods
  • Myasthenia gravis has an impact on family planning and care for children.

Methods:

In cooperation with the German Myasthenia Gravis Society, a questionnaire prepared by the Charité will be sent to its members with a request for completion and an anonymous return. Similar projects have already been implemented in the past (response rate> 30%). About 3,300 patients should be contacted.

The returned questionnaires are then statistically evaluated and presented as part of a publication. For the evaluation of the hypotheses suitable descriptive, univariate analysis methods are used. Furthermore, with sufficient case numbers, multivariate analyzes (e.g., logistic regression) are also planned.

The questionnaire contains general information and questions about:

  • Education and employment
  • Social situation
  • Social Support
  • Economic aspects
  • Symptoms and severity, course, treatment of myasthenia
  • Quality of life
  • Fatigue and depression
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients with Myasthenia Gravis being member at the German myasthenia gravis socitey (Deutsche Myasthenie Gesellschaft)
Condition Myasthenia Gravis
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: August 8, 2019)
1680
Original Estimated Enrollment
 (submitted: June 6, 2019)
1200
Actual Study Completion Date July 31, 2019
Actual Primary Completion Date July 31, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients with Myasthenia Gravis
  • Age ≥18 years

Exclusion Criteria:

  • none
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Germany
Removed Location Countries  
 
Administrative Information
NCT Number NCT03979521
Other Study ID Numbers Mya-BoD
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Andreas Meisel, Charite University, Berlin, Germany
Study Sponsor Charite University, Berlin, Germany
Collaborators NeuroCure Clinical Research Center, Charite, Berlin
Investigators
Principal Investigator: Andreas Meisel, Prof. Dr. med. Charite University, Berlin, Germany
PRS Account Charite University, Berlin, Germany
Verification Date December 2019